Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pittsburgh
Sahlgrenska University Hospital
Federation Francophone de Cancerologie Digestive
Merck Sharp & Dohme LLC
Xiamen University
Shanghai Bovax Biotechnology Co., Ltd.
AIDS Malignancy Consortium
Institut de Cancérologie de Lorraine
Beijing Health Guard Biotechnology, Inc
Sixth Affiliated Hospital, Sun Yat-sen University
UNICANCER
Blokhin's Russian Cancer Research Center
AIDS Malignancy Consortium
Merck Sharp & Dohme LLC
University of Erlangen-Nürnberg Medical School
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
INSYS Therapeutics Inc
National Cancer Institute (NCI)